Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has announced that the FDA has issued a not-approvable letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia.
Subscribe to our email newsletter
Schering-Plough has acquired sugammadex in November 2007 through its acquisition of Organon BioSciences, which developed the product.
Thomas Koestler, executive vice president and president of Schering-Plough Research Institute, said: “We remain committed to bringing this important medical advance to those who are waiting for it in the US, and plan to work with the agency to address the issues, which are primarily related to hypersensitivity/allergic reactions.”